Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in
 patients presenting with Multiple Myeloma and impaired renal function, the safety of
 Revlimid® in the enrolled patients population.

 and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM
 and impaired renal function at completion of 3 cycles of treatment.
Inclusion Criteria:

 -  Documented diagnosis of relapsed or refractory multiple myeloma (MM).

 -  Age > 18 years at the time of signing the informed consent form

 -  Stable renal function

 Exclusion Criteria:

 -  Documented amyloidosis

 -  Any prior use of Revlimid ®

 -  Any contraindication to Revlimid ® and especially:

 -  Lack of acceptable method of birth control for female of childbearing potential (FCPB)

 -  Men who don't agree to use condom during the study and 4 weeks after the last
 study drug intake if their partner is a FCPB.

 -  Pregnant or breast feeding women